Back to top<\/a><\/p>\n <\/p>\n
<\/p>\n
How Engineering Design and Biochemistry Come Together to Improve Patient Care; Atellica\u2122 Solution Assays in a New Light
\nSiemens
\nMonday June 4, 1600-1700<\/strong><\/p>\n <\/p>\n
\n
Frank Vitzhum,<\/strong> Global Assay Development, Siemens Healthineers<\/a><\/p>\n <\/p>\n
General Objectives:<\/strong><\/p>\nAt the conclusion of this session, participants will be able to:<\/p>\n
\n- Learn basic procedural aspects of the development of assay products.<\/li>\n
- Understand how certain key features of certain critical components of an assay formulation, in particular acridinium-esters and their conjugates, impact the performance of an assay.<\/li>\n
- Learn how engineering features can improve the assay time and the precision of an assay without the need for changing formulations.<\/li>\n<\/ul>\n
The workshop will provide an overview of the development process for assays at Siemens Healthineers. With a focus on immunoassays using the acridinium-ester technology, approaches are discussed on how performance characteristics, in particular assay sensitivity, as well as manufacturability and lot-to-lot consistency can be improved. This will be discussed using examples like the High Sensitivity Troponin I assay. Furthermore, examples from Atellica Solution will be presented to explain benefits of engineering design on time to first result and precision without changing the biochemistry of an assay.<\/p>\n
<\/a>Back to top<\/a><\/p>\n <\/p>\n
<\/p>\n
Management of Dysglycemia in Critically Ill Patients \u2013 Importance of Glucose Meter Accuracy
\nNova Biomedical
\nTuesday June 5, 0730-0830<\/strong><\/p>\n <\/p>\n
\n
Evan Ntrivalas,<\/strong> MD, PhD, HCLD\/CC(ABB), D(ABLMLI), Director of Medical and Scientific Affairs, Nova Biomedical, USA<\/a><\/p>\n <\/p>\n
General Objectives:<\/strong><\/p>\nAt the conclusion of this session, participants will be able to:<\/p>\n